Literature DB >> 23473990

The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions.

Paolo Vercellini1, Fulvia Milena Cribiù, Alessandro Del Gobbo, Maria Luisa Carcangiu, Edgardo Somigliana, Silvano Bòsari.   

Abstract

OBJECTIVE: To determine whether the oncofetal protein IMP3 is detectable in endometriomas with or without histological atypia and whether IMP3 staining can be used as a triage tool to identify foci of atypical endometriosis in doubtful cases.
DESIGN: Retrospective study.
SETTING: Academic department and referral center for endometriosis. PATIENT(S): A consecutive series of 516 women who underwent excision of 874 endometriomas. INTERVENTION(S): Histological review by three expert pathologists and immunohistochemical staining for IMP3. MAIN OUTCOME MEASURE(S): Test performance of IMP3 immunohistochemistry versus first-round histology. RESULT(S): The prevalence of atypical endometriosis was 1.7% (95% confidence interval [CI], 0.9%-3.3%) based on the number of women and 1.0% (95% CI, 0.5%-1.9%) based on the number of cysts. Three cases of atypical endometriosis were identified at first-round histological examination. Immunohistochemistry detected seven of the eight cases diagnosed as preneoplastic atypia at second-round histology and one case diagnosed as reactive atypia at second-round histology. The sensitivity of first-round histology was 33.3%, compared with 88.9% of IMP3 immunohistochemistry. CONCLUSION(S): Immunohistochemical staining for IMP3 expression is a simple, inexpensive, and sensitive test that can be used in routine clinical practice as a triage tool to discriminate between cytological/structural atypia and confounding benign conditions.
Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23473990     DOI: 10.1016/j.fertnstert.2013.02.002

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.

Authors:  Sara Massironi; Alessandro Del Gobbo; Federica Cavalcoli; Stefano Fiori; Dario Conte; Alessio Pellegrinelli; Massimo Milione; Stefano Ferrero
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

2.  Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?

Authors:  Massimo Milione
Journal:  Endocrine       Date:  2017-04-17       Impact factor: 3.633

3.  IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.

Authors:  Qin Zhu; Yuqing Qu; Qiongyan Zhang; Linghui Lu; Weiwei Weng; Hao Zhang; Lihong Zhang; Yan Ning; Yiqin Wang
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 4.  Endometriosis: pathogenesis and treatment.

Authors:  Paolo Vercellini; Paola Viganò; Edgardo Somigliana; Luigi Fedele
Journal:  Nat Rev Endocrinol       Date:  2013-12-24       Impact factor: 43.330

5.  The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas.

Authors:  Alessandro Del Gobbo; Valentina Vaira; Lucia Ferrari; Carlo Patriarca; Andrea Di Cristofori; Dario Ricca; Manuela Caroli; Paolo Rampini; Silvano Bosari; Stefano Ferrero
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

Review 6.  IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives.

Authors:  Caterina Mancarella; Katia Scotlandi
Journal:  Front Cell Dev Biol       Date:  2020-01-15

Review 7.  A Systematic Review of Atypical Endometriosis-Associated Biomarkers.

Authors:  Ludovica Bartiromo; Matteo Schimberni; Roberta Villanacci; Giorgia Mangili; Stefano Ferrari; Jessica Ottolina; Noemi Salmeri; Carolina Dolci; Iacopo Tandoi; Massimo Candiani
Journal:  Int J Mol Sci       Date:  2022-04-17       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.